T&L Biotechnology, founded in 2011 and headquartered in the United States, positions itself as a strategic partner in the burgeoning Biopharma and Biotechnology sectors, specializing in cell and gene therapy (CGT). With its motto "Provide One-Stop Products and Services for CGT Research", the company provides comprehensive solutions, from cell separation magnetic beads to serum-free media, catering to the intricate needs of CGT research and development.
The company's operational prowess is underscored by a 3,200-square-meter GMP-level clean workshop and rigorous adherence to the ISO 13485 and ISO 9001 standards, highlighting its commitment to quality. Noteworthy is their possession of FDA DMF filings, which enhances credibility and regulatory compliance.
Recently, T&L Biotechnology secured a CNY90.00M Series A investment, with backing from reputable investors such as Fortune Venture Capital and Harvest Capital, indicating robust investor confidence and potential for scaling its operations further.